drugset / Trial / NCT00891306

Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects

NCT00891306

NaSingle-groupOpen-labelTreatment

Summary

This trial is designed to expand the currently available data on the safety and efficacy of alipogene tiparvovec treatment in lipoprotein lipase deficiency (LPLD) and to further the understanding of possible mechanisms of action of the therapy.

Timeline

Start
2009-02
Primary completion
2010-08
Completion
2011-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alipogene Tiparvovec Unknown 1e+12 vg/kg Intramuscular
Background Cyclosporine Peptide 3 mg/kg Oral
Background Methylprednisolone Other / unclassified 1 mg/kg Intravenous
Background Mycophenolate Mofetil Small molecule 2 g Oral